Atlanticus EPS Beats by $0.08 as Insiders Sell $7.9M in Stock
Atlanticus Holdings (ATLC) delivered a $2.50 EPS, beating by $0.08, on solid profitability metrics. Simultaneously, insiders including the CFO sold $7.87 million in shares, raising questions about alignment. With a P/E of 16.69 and beta of 2.11, the stock remains a volatile play in consumer credit.
Beat this week
Last 7 days · Earnings
Impact 5.6/10 (+0.4 vs prior). Counts are stories in our record, not a market forecast.
Open the change reportCoverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 35 percentage points.
This story sits in Earnings — the counts compare this beat's last 7 days with the previous 7 in our verified record, not a market forecast.
Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.
Finance briefing
Key takeaways
- Atlanticus Holdings (ATLC) delivered a $2.50 EPS, beating by $0.08, on solid profitability metrics.
- Simultaneously, insiders including the CFO sold $7.87 million in shares, raising questions about alignment.
- With a P/E of 16.69 and beta of 2.11, the stock remains a volatile play in consumer credit.
In this briefing
Mentioned
Key Intelligence
Key Facts
- 1Atlanticus reported Q2 EPS of $2.50, beating the consensus estimate of $2.42 by $0.08.
- 2Atlanticus has a net margin of 5.86% and a return on equity of 23.43%.
- 3Aligos Therapeutics beat consensus EPS expectations by $0.95, but no further financial details were provided.
- 4Atlanticus insiders sold 75,000 shares worth $7,868,627 over the last quarter, including sales by the CFO and a major shareholder.
- 5Atlanticus stock traded at $111.79 on the earnings day, with a 50-day moving average of $97.22 and a 200-day moving average of $74.72.
- 6Atlanticus market cap stands at $1.69 billion, with a P/E ratio of 16.69 and a beta of 2.11.
Analysis
- Strong EPS beat and high ROE of 23.4%
- Market cap of $1.69B with reasonable P/E of 16.7
- High insider ownership at 51% aligns management with shareholders
- Insiders sold $7.9M worth of shares near quarter-end
- Beta of 2.11 indicates high volatility
- Debt-to-equity of 1.08 could be a concern if credit conditions tighten
Analysis
For market participants, Atlanticus’s earnings beat is a testament to strong credit underwriting and the resilience of consumer finance. But the insider selling—$7.87 million in aggregate last quarter—adds a layer of complexity: are executives cashing in on a high stock price, or is this a signal of a peak? With a 51% insider ownership, the sell-off is notable but not necessarily devastating for investor confidence.
Two companies, Atlanticus Holdings (ATLC) and Aligos Therapeutics (ALGS), reported quarterly earnings that exceeded analyst estimates, showcasing divergent paths in their respective industries. Atlanticus, a credit services provider, posted earnings per share (EPS) of $2.50, beating the Zacks consensus estimate of $2.42 by $0.08. This beat was accompanied by robust financial metrics: a 23.43% return on equity, a net margin of 5.86%, and a stock price trading near its 52-week high at $111.79 on the day of the release, up $0.48. The company’s ordinary trading volume of 150,852 shares far exceeded the average of 105,286, indicating heightened investor interest. Atlanticus’s market capitalization stands at $1.69 billion, with a price-to-earnings ratio of 16.69 and a beta of 2.11, reflecting above-average volatility. The company’s debt-to-equity ratio of 1.08 and current ratio of 1.24 suggest manageable leverage and liquidity.
CFO William Mccamey sold 10,000 shares on June 30, 2026, at $103.01 per share, totaling $1,030,100, reducing his stake by 7.28%.
Aligos Therapeutics, a biopharmaceutical firm focused on liver diseases, announced a far more dramatic beat: it exceeded consensus EPS expectations by a remarkable $0.95. While financial details beyond the EPS beat were not disclosed in the available sources, the magnitude of the outperformance is striking for a clinical-stage biotech, where revenue streams are often minimal and earnings are closely tied to collaboration milestones, licensing agreements, or expense management. Aligos’s stock performance and market reaction could not be independently assessed from the provided materials, but such beats often signal progress in clinical programs or favorable regulatory events.
What to Watch
Insider transaction activity at Atlanticus adds a layer of intrigue. CFO William Mccamey sold 10,000 shares on June 30, 2026, at $103.01 per share, totaling $1,030,100, reducing his stake by 7.28%. Major shareholder Frank J. Hanna III sold 15,676 shares on July 1, 2026, at $104.26 per share, worth $1,634,379.76, cutting his position by 5.70%. Together with other insider sales, total dispositions reached 75,000 shares worth $7.87 million over the prior quarter. While insiders still hold 51% of the company, the sales near the end of the fiscal quarter could be interpreted as profit-taking or portfolio diversification. In the context of a strong earnings beat, however, such sales might not signal bearish sentiment but rather routine financial planning.
From a market perspective, both beats reflect resilience in their sectors. The credit services industry benefits from stable consumer credit demand and interest rate dynamics, while biotech continues to attract capital for innovative therapies. Atlanticus’s solid fundamentals suggest continued profitability, while Aligos’s massive beat hints at operational or clinical breakthroughs that could materially improve its risk profile. Investors and analysts will watch for follow-up disclosures, particularly from Aligos, to understand the drivers behind the earnings surprise and to gauge sustainability. The insider selling at Atlanticus, though significant, may be mitigated by the remaining high insider ownership and the company’s strong performance trajectory.
Cite This Page
"Atlanticus EPS Beats by $0.08 as Insiders Sell $7.9M in Stock." Finance Intelligence Brief, August 9, 2026. https://getfinancebrief.com/story/atlanticus-earnings-insider-selling-7-9m
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |